Instruction 1(b).

П

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1034

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

					01 00					inpully / tot									
1. Name and Address of Reporting Person [*] Campbell Bradley L					2. Issuer Name and Ticker or Trading Symbol AMICUS THERAPEUTICS, INC. [FOLD									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
]									X Direc	lor	10% (Jwner					
(Last) (First) (Middle)						3. Date of Earliest Transaction (Month/Day/Year)									cer (give title	Other below	(specify)		
. ,	FISH STRF	,	maaro)		03/15/2024									President and CEO					
1, 1102	10110110				4. If Amondmont, Date of Original Filed (Month/Dou/Veer)									6 Individual or Jaint/Croup Filing (Chaol: Applicable					
(Street)					4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)					
PRINCE	TON NJ	0	8542										X Form	Form filed by One Reporting Person					
													Form filed by More than One Rep Person						
(City) (State) (Zip)						Rule 10b5-1(c) Transaction Indication													
			Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.																
		Table	I - No	n-Deriva	ative S	Secu	rities Acc	uired	, Dis	posed o	of, d	or Ber	nefici	ally Own	ed				
1. Title of Security (Instr. 3) Date (Month/D					Execution Date,			3. Transaction Code (Instr. 8) 4. Securitie Disposed C 5)						Benefi	ties cially I Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
					Code V		Amount		(A) or (D)	Price	Transa	ction(s) 3 and 4)		(Instr. 4)					
Common Stock 03/15/2					2024			F		13,375	5	D	\$11.	611.48 886,65		D			
		Tal	ble II -				ties Acqu warrants,								d				
								-				. 300u	nuos	-					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative	3. Transaction Date (Month/Day/Year)	if any	emed ion Date, /Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired	6. Date Exercisable a Expiration Date (Month/Day/Year)			S S	7. Title and Amount of Securities Underlying Derivative		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned	Ownershi Form:	Beneficial Ownershi		

	Derivative Security				Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)				Deriva Secur 3 and	rity (Instr.	Owned Following Reported Transaction(s) (Instr. 4)	or Indirect (I) (Instr. 4)	(Instr. 4)		
			Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					

Explanation of Responses:

<u>/s/ Christian Formica</u>, <u>Attorney-in-Fact</u>

03/19/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.